Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Joseph Murray

Gastroenterology Rochester, MN Medical Doctor

NPI 1538149018 CMS profile 342251

200 1St St Sw, Rochester, MN 55905

Open in the dashboard

General payments

$234,305

63 records reported · program years 2019–2025

Research payments

$2,200

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$994,300 paid to institutions, not to them · program years 2022–2025

Through program year 2025, Joseph Murray of Rochester, MN is reported in the CMS Open Payments database as having received $234,305 across 63 general payments and $2,200 in research payments paid to them. Separately, studies naming them as principal investigator received $994,300 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 98th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $42,260 6
2024 General $43,135 8
2023 General $54,996 24
2022 General $45,442 13
2022 Research $2,200 1
2021 General $26,625 3
2020 General $15,650 4
2019 General $6,197 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Joseph Murray
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Joseph Murray were reported at $42,260. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Joseph Murray Gastroenterology median Middle half National median
2019 $6,197 $417 $126–$1,100 $163
2020 $15,650 $224 $74–$624 $114
2021 $26,625 $352 $106–$1,054 $132
2022 $45,442 $448 $129–$1,270 $149
2023 $54,996 $533 $150–$1,390 $160
2024 $43,135 $605 $160–$1,606 $164
2025 $42,260 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Chugai Pharmaceutical Co., Ltd. $126,273 26 payments
  2. Genzyme Corporation $32,035 14 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $23,062 8 payments
  4. GlaxoSmithKline, LLC. $23,016 7 payments
  5. Sanofi US Services Inc. $15,244 3 payments
  6. Janssen Research & Development, LLC $6,250 1 payment
  7. E.R. Squibb & Sons, L.L.C. $3,375 1 payment
  8. Ucb SA $2,300 1 payment
  9. Amgen Inc. $2,000 1 payment
  10. Inova Diagnostics, Inc. $750 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $224,678 39 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $4,106 2 payments
  3. Travel and Lodging $3,691 8 payments
  4. Food and Beverage $1,079 13 payments
  5. Honoraria $750 1 payment
Products named General payments · program years 2019–2025
  1. DUPIXENT $16,017 8 payments
  2. Non-Covered Product $3,026 3 payments
  3. Cimzia $2,300 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Takeda Pharmaceuticals U.S.A., Inc. $2,200 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

223

Median for Gastroenterology: 569

Drug cost

$23,502

Median for Gastroenterology: $104,976

Branded share of claims

10.8%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Motegrity Prucalopride Succinate Brand 24 $11,941
Sucralfate Generic 34 $8,684
Mirtazapine Generic 24 $787
Pantoprazole Sodium Generic 52 $737
Famotidine Generic 36 $526
Omeprazole Generic 29 $436
Pentoxifylline Generic 12 $291
Dicyclomine Hcl Generic 12 $101

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 21 billing codes

Paid by Medicare

$14,123

Medicare's payments for the services billed

Medicare patients

137

Average age 70

Services billed

197

86 women, 51 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 55%
Arthritis 45%
Osteoporosis 28%
Chronic kidney disease 26%
Depression 25%
Diabetes 23%
Ischemic heart disease 23%
COPD 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

64 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Minnesota

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record